JP2022549510A5 - - Google Patents

Info

Publication number
JP2022549510A5
JP2022549510A5 JP2022519572A JP2022519572A JP2022549510A5 JP 2022549510 A5 JP2022549510 A5 JP 2022549510A5 JP 2022519572 A JP2022519572 A JP 2022519572A JP 2022519572 A JP2022519572 A JP 2022519572A JP 2022549510 A5 JP2022549510 A5 JP 2022549510A5
Authority
JP
Japan
Application number
JP2022519572A
Other languages
Japanese (ja)
Other versions
JP2022549510A (ja
JPWO2021067242A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/053224 external-priority patent/WO2021067242A1/en
Publication of JP2022549510A publication Critical patent/JP2022549510A/ja
Publication of JP2022549510A5 publication Critical patent/JP2022549510A5/ja
Publication of JPWO2021067242A5 publication Critical patent/JPWO2021067242A5/ja
Ceased legal-status Critical Current

Links

JP2022519572A 2019-09-30 2020-09-29 アミド結合したアミノベンズアゼピン免疫複合体、及びその使用 Ceased JP2022549510A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962908253P 2019-09-30 2019-09-30
US62/908,253 2019-09-30
PCT/US2020/053224 WO2021067242A1 (en) 2019-09-30 2020-09-29 Amide-linked, aminobenzazepine immunoconjugates, and uses thereof

Publications (3)

Publication Number Publication Date
JP2022549510A JP2022549510A (ja) 2022-11-25
JP2022549510A5 true JP2022549510A5 (https=) 2023-09-29
JPWO2021067242A5 JPWO2021067242A5 (https=) 2023-09-29

Family

ID=72840675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519572A Ceased JP2022549510A (ja) 2019-09-30 2020-09-29 アミド結合したアミノベンズアゼピン免疫複合体、及びその使用

Country Status (11)

Country Link
US (1) US20220347310A1 (https=)
EP (1) EP4038053A1 (https=)
JP (1) JP2022549510A (https=)
KR (1) KR20220077131A (https=)
CN (1) CN114746404A (https=)
AU (1) AU2020359446A1 (https=)
BR (1) BR112022006001A2 (https=)
CA (1) CA3152601A1 (https=)
IL (1) IL291760A (https=)
MX (1) MX2022003740A (https=)
WO (1) WO2021067242A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
CN115996756A (zh) * 2020-05-08 2023-04-21 博尔特生物治疗药物有限公司 弹性蛋白酶底物肽连接子免疫缀合物及其用途
US20220195066A1 (en) * 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
CA3212926A1 (en) * 2021-03-26 2022-09-29 Gary Brandt 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
CN117940168A (zh) * 2021-03-26 2024-04-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
CA3218829A1 (en) * 2021-05-19 2022-11-24 Zhaolong Tong Nitrogen-containing compound, conjugate containing said compound, and application thereof
CN118475372A (zh) * 2021-10-29 2024-08-09 博尔特生物治疗药物有限公司 具有半胱氨酸突变抗体的tlr激动剂免疫缀合物及其用途
WO2023109944A1 (zh) * 2021-12-16 2023-06-22 映恩生物制药(苏州)有限公司 Tlr调节剂及其用途
TW202339806A (zh) * 2022-02-09 2023-10-16 美商博特生物治療公司 8—磺醯基—苯并氮呯免疫結合物及其用途
CN118843480A (zh) * 2022-02-09 2024-10-25 博尔特生物治疗药物有限公司 高分子负载的8-磺酰基-苯并氮杂䓬化合物及其用途
WO2024067841A1 (zh) * 2022-09-30 2024-04-04 上海迪诺医药科技有限公司 苯并氮杂卓衍生物、含其的偶联物及其应用
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US723288A (en) 1901-10-26 1903-03-24 Harry South Lewis Cipher-key for cryptographic codes.
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
PT1308456E (pt) 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CA2399940A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
WO2005086875A2 (en) 2004-03-11 2005-09-22 City Of Hope A humanized anti-cea t84.66 antibody and uses thereof
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
WO2006073921A2 (en) 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
LT1976880T (lt) 2005-12-21 2016-10-10 Amgen Research (Munich) Gmbh Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
MX2010003718A (es) 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
HUE025678T2 (en) 2010-02-04 2016-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック, インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
RS56793B1 (sr) 2011-03-02 2018-04-30 Roche Glycart Ag Cea antitela
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
PT2740793T (pt) 2011-08-04 2018-02-23 Toray Industries Composição de fármacos para o tratamento e/ou a prevenção de cancro
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740794T (pt) 2011-08-04 2018-06-14 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
PT2818483T (pt) 2012-02-21 2017-10-09 Toray Industries Composição medicinal para tratamento e/ou prevenção de cancro
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
HUE044611T2 (hu) 2012-02-21 2019-11-28 Toray Industries Gyógyászati készítmény rák kezelésére
PL2876447T3 (pl) 2012-07-19 2020-05-18 Toray Industries, Inc. Sposób wykrywania nowotworu
RU2646466C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
HUE033369T2 (en) 2012-11-20 2017-11-28 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
ES2704909T3 (es) 2013-08-09 2019-03-20 Toray Industries Composición farmacéutica para el tratamiento y/o la prevención del cáncer
US9676863B2 (en) 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
EP3233835B1 (en) * 2014-12-18 2019-01-23 F.Hoffmann-La Roche Ag Benzazepine sulfonamide compounds
KR102581546B1 (ko) * 2015-03-06 2023-09-25 에프. 호프만-라 로슈 아게 벤즈아제핀 다이카복스아미드 화합물
JP2018532803A (ja) * 2015-11-02 2018-11-08 ベンティアールエックス ファーマシューティカルズ, インコーポレイテッドVentiRx Pharmaceuticals,Inc. 癌を処置するためのtlr8アゴニストの使用
EP3464274B1 (en) * 2016-05-23 2020-05-27 H. Hoffnabb-La Roche Ag Benzazepine dicarboxamide compounds with secondary amide function
JP6918838B2 (ja) * 2016-05-23 2021-08-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 第三級アミド基を有するベンズアゼピンジカルボキサミド化合物
JP7012668B2 (ja) * 2016-06-12 2022-02-14 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物
KR20240005247A (ko) 2016-10-28 2024-01-11 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
WO2018140831A2 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
ES2894731T3 (es) * 2017-03-15 2022-02-15 Silverback Therapeutics Inc Compuestos de benzazepina, conjugados y usos de los mismos
WO2019084060A1 (en) * 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
WO2020056194A1 (en) * 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
US20200113912A1 (en) * 2018-09-12 2020-04-16 Silverback Therapeutics, Inc. Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
AU2020291014B2 (en) * 2019-06-13 2025-06-05 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
JP2022549510A5 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021015450A8 (https=)
BR102021013929A2 (https=)
BR102021012571A2 (https=)
BR102021012230A2 (https=)
BR102021012003A2 (https=)